300436 Fujian Cosunter Pharmaceutical Co.,Ltd.
Closed 04-15 15:00:00
31.29
-0.34
-1.07%
High
32.32
Low
31.00
Vol
4.72M
Open
31.80
D1 Closing
31.63
Amplitude
4.17%
Mkt Cap
4.98B
Tradable Cap
4.29B
Total Shares
159.00M
T/O
149.00M
T/O Rate
3.44%
Tradable Shares
137.00M
P/B
11.3
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
Loading ...
News
New Post(s)
Profile
Cosunter Pharmaceutical to Raise 977 Million Yuan From Planned Share Issuance; Shares Down 4%
MT Newswires Live · 04-03
Cosunter Pharmaceutical to Raise 977 Million Yuan From Planned Share Issuance; Shares Down 4%
Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs
MT Newswires Live · 03-18
Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs
Cosunter Pharma's Unit Gets Nod to Trial Coronavirus Drug in Thailand
MT Newswires Live · 02-06
Cosunter Pharma's Unit Gets Nod to Trial Coronavirus Drug in Thailand
China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%
MT Newswires Live · 2024-12-16
China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%
Load more
Introduction
Company Name.
福建广生堂药业股份有限公司
Industry:
医药制造业
Listing Date:
2015-04-22
Main Business:
福建广生堂药业股份有限公司的主营业务为核苷类抗乙肝病毒药物的研发、生产与销售;公司的主要产品为抗乙肝病毒药物、保肝护肝药物、消化系统药物、呼吸系统药物、心血管药物、医学检验服务;公司目前是国内专注于肝脏健康领域的医药企业,是国内唯一同时拥有阿德福韦酯、拉米夫定、恩替卡韦、替诺福韦四大抗乙肝病毒临床优选用药的医药企业。公司是国家高新技术企业、国家企业技术中心、国家知识产权示范企业、福建省工业龙头培育企业(第一批)、福建省循环经济示范企业(第三批)。2023年2月,我司“富马酸替诺福韦二吡呋酯胶囊原料药及胶囊剂的研究开发项目”,荣获福建省科学技术进步奖三等奖;2023年7月,公司获得“2020—2021年度福建省守合同重信用企业”称号。
Issue price:
21.47
Invest in Global Markets with Tiger Brokers!
Open App
{"stockData":{"symbol":"300436","market":"SZ","secType":"STK","nameCN":"Fujian Cosunter Pharmaceutical Co.,Ltd.","latestPrice":31.29,"timestamp":1744700583000,"preClose":31.63,"halted":0,"volume":4715000,"delay":0,"changeRate":-0.0107,"floatShares":137000000,"shares":159000000,"eps":-1.4027,"marketStatus":"Closed","change":-0.34,"latestTime":"04-15 15:00:00","open":31.8,"high":32.32,"low":31,"amount":149000000,"amplitude":0.0417,"askPrice":31.3,"askSize":20,"bidPrice":31.29,"bidSize":62,"shortable":0,"etf":0,"ttmEps":-1.4027,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744767000000},"marketStatusCode":5,"adr":0,"adjPreClose":31.63,"symbolType":"stock","openAndCloseTimeList":[[1744680600000,1744687800000],[1744693200000,1744700400000]],"highLimit":34.79,"lowLimit":28.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":159267000,"isCdr":false,"pbRate":11.3,"roa":"--","roe":"--","epsLYR":-2.1887,"committee":0.141304,"marketValue":4983000000,"turnoverRate":0.0345,"status":1,"floatMarketCap":4278000000},"requestUrl":"/m/hq/s/300436","defaultTab":"news","newsList":[{"id":"2524406477","title":"Cosunter Pharmaceutical to Raise 977 Million Yuan From Planned Share Issuance; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524406477","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524406477?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 13:36","pubTimestamp":1743658587,"startTime":"0","endTime":"0","summary":"Fujian Cosunter Pharmaceutical plans to raise 976.9 million yuan from a planned share issuance, according to a Shenzhen Stock Exchange filing on Tuesday.The pharmaceutical company plans to issue 47.8 million shares.The plan is still subject to the approval of the Chinese securities regulator, the filing said.The company's shares fell over 4% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2520695444","title":"Chinese Drug Regulator Accepts Clinical Trial Application of Cosunter Pharmaceutical's Unit for Two Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2520695444","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520695444?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 14:49","pubTimestamp":1742280587,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the application of Fujian Cosunter Pharmaceutical's unit, Fujian Guangsheng ZhongLin Biotechnology, for the clinical trials of two drugs.The pharmaceutical company plans to trial GST-HG141 narecovir tablets and GST-HG131 tablets as treatment of hepatitis B patients, according to a Shenzhen Stock Exchange disclosure on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2509219639","title":"Cosunter Pharma's Unit Gets Nod to Trial Coronavirus Drug in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2509219639","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509219639?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 14:16","pubTimestamp":1738822565,"startTime":"0","endTime":"0","summary":"Fujian Cosunter Pharmaceutical's unit, Fujian Guangsheng Zhonglin Biotechnology, received approval from Thailand's drug administration to conduct clinical trials on a drug for the new coronavirus, according to a Shenzhen Stock Exchange disclosure on Wednesday.The atetegravir tablets or ritonavir tablets, traded as Tazovid, will be tested in Thailand, the pharmaceutical company said.The company's shares rose 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2491637105","title":"China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491637105","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491637105?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 14:53","pubTimestamp":1734332028,"startTime":"0","endTime":"0","summary":"China's medical products administrator granted Fujian Cosunter Pharmaceutical breakthrough therapy designation for its hepatitis B drug, according to a Monday filing with the Shenzhen Stock Exchange.The drug, with the generic name Neracorvir, will still have to undergo registration clinical research, the filing said.Shares fell 5% during Monday's afternoon trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300436"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-04-22","address":"福建省宁德市柘荣县富源工业园区1-7幢","stockEarnings":[{"period":"1week","weight":0.1745},{"period":"1month","weight":-0.16},{"period":"3month","weight":-0.0337},{"period":"6month","weight":0.1861},{"period":"1year","weight":0.9114},{"period":"ytd","weight":-0.0422}],"companyName":"福建广生堂药业股份有限公司","boardCode":"AI0027","perCapita":"6628股","boardName":"医药制造业","registeredCapital":"15926万元","compareEarnings":[{"period":"1week","weight":0.0388},{"period":"1month","weight":-0.0444},{"period":"3month","weight":0.0126},{"period":"6month","weight":0.031},{"period":"1year","weight":0.0688},{"period":"ytd","weight":-0.0251}],"survey":" 福建广生堂药业股份有限公司的主营业务为核苷类抗乙肝病毒药物的研发、生产与销售;公司的主要产品为抗乙肝病毒药物、保肝护肝药物、消化系统药物、呼吸系统药物、心血管药物、医学检验服务;公司目前是国内专注于肝脏健康领域的医药企业,是国内唯一同时拥有阿德福韦酯、拉米夫定、恩替卡韦、替诺福韦四大抗乙肝病毒临床优选用药的医药企业。公司是国家高新技术企业、国家企业技术中心、国家知识产权示范企业、福建省工业龙头培育企业(第一批)、福建省循环经济示范企业(第三批)。2023年2月,我司“富马酸替诺福韦二吡呋酯胶囊原料药及胶囊剂的研究开发项目”,荣获福建省科学技术进步奖三等奖;2023年7月,公司获得“2020—2021年度福建省守合同重信用企业”称号。","serverTime":1744762210517,"listedPrice":21.47,"stockholders":"20627人(较上一季度增加23.26%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fujian Cosunter Pharmaceutical Co.,Ltd.(300436),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fujian Cosunter Pharmaceutical Co.,Ltd.(300436) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fujian Cosunter Pharmaceutical Co.,Ltd.,300436,Fujian Cosunter Pharmaceutical Co.,Ltd.股票,Fujian Cosunter Pharmaceutical Co.,Ltd.股票老虎,Fujian Cosunter Pharmaceutical Co.,Ltd.股票老虎国际,Fujian Cosunter Pharmaceutical Co.,Ltd.行情,Fujian Cosunter Pharmaceutical Co.,Ltd.股票行情,Fujian Cosunter Pharmaceutical Co.,Ltd.股价,Fujian Cosunter Pharmaceutical Co.,Ltd.股市,Fujian Cosunter Pharmaceutical Co.,Ltd.股票价格,Fujian Cosunter Pharmaceutical Co.,Ltd.股票交易,Fujian Cosunter Pharmaceutical Co.,Ltd.股票购买,Fujian Cosunter Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fujian Cosunter Pharmaceutical Co.,Ltd.(300436),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fujian Cosunter Pharmaceutical Co.,Ltd.(300436) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}